

-
75. (New) An antibody or antigen binding fragment thereof which binds to a mammalian chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor.
76. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment has specificity for mammalian chemokine receptor 5 (CCR5).
77. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the mammalian chemokine receptor 5 (CCR5) is a human chemokine receptor 5 (CCR5).
- BI 78. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the chemokine is selected from the group consisting of MIP-1 α , MIP-1 β and RANTES or a combination thereof.
79. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
80. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.
81. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.

82. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
83. (New) The antibody or antigen binding fragment thereof of Claim 82, wherein the humanized antibody comprises at least six complementarity determining regions of a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 and a portion of an immunoglobulin of human origin.
84. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment binds the second extracellular loop of mammalian chemokine receptor 5 (CCR5).
85. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
86. (New) The antibody or antigen binding fragment thereof of Claim 75, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.
87. (New) A composition comprising an antibody or antigen binding fragment thereof which binds to a mammalian chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor.
88. (New) The composition of Claim 87, wherein the antibody or antigen binding fragment has specificity for mammalian chemokine receptor 5 (CCR5).

89. (New) The composition of Claim 87, wherein the mammalian chemokine receptor 5 (CCR5) is a human chemokine receptor 5 (CCR5).
90. (New) The composition of Claim 87, wherein the chemokine is selected from the group consisting of MIP-1 α , MIP-1 β and RANTES or a combination thereof.
91. (New) The composition of Claim 87, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.
92. (New) The composition of Claim 87, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.
- BI 93. (New) The composition of Claim 87, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
94. (New) The composition of Claim 87, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
95. (New) The composition of Claim 94, wherein the humanized antibody comprises at least six complementarity determining regions of a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 and a portion of an immunoglobulin of human origin.
96. (New) The composition of Claim 87, wherein the antibody or antigen binding fragment binds the second extracellular loop of mammalian chemokine receptor 5 (CCR5).
97. (New) The composition of Claim 87, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).

Rule 112e 98
99. (New) The composition of Claim 87, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.

99. (New) A test kit for use in detecting the presence of a mammalian chemokine receptor 5 (CCR5) in a biological sample comprising:

- BI
- a) an antibody or antigen binding fragment thereof which binds to a mammalian chemokine receptor 5 (CCR5), wherein said antibody or antigen binding fragment inhibits binding of a chemokine to the receptor and inhibits one or more functions associated with binding of the chemokine to the receptor; and
 - b) one or more ancillary reagents suitable for detecting the presence of a complex between said antibody or antigen binding fragment and said receptor.

100. (New) The test kit of Claim 99, wherein the antibody or antigen binding fragment has specificity for mammalian chemokine receptor 5 (CCR5).

101. (New) The test kit of Claim 99, wherein the mammalian chemokine receptor 5 (CCR5) is a human chemokine receptor 5 (CCR5).

102. (New) The test kit of Claim 99, wherein said chemokine is selected from the group consisting of MIP-1 α , MIP-1 β and RANTES or a combination thereof.

103. (New) The test kit of Claim 99, wherein the antibody or antigen binding fragment is a monoclonal antibody or antigen binding fragment thereof.

104. (New) The test kit of Claim 99, wherein the antibody or antigen binding fragment is a chimeric antibody or antigen binding fragment thereof.

105. (New) The test kit of Claim 99, wherein the antibody or antigen binding fragment is a human antibody or antigen binding fragment thereof.
106. (New) The test kit of Claim 99, wherein the antibody or antigen binding fragment is a humanized antibody or antigen binding fragment thereof.
107. (New) The test kit of Claim 106, wherein the humanized antibody comprises at least six complementarity determining regions of a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 and a portion of an immunoglobulin of human origin.
108. (New) The test kit of Claim 99, wherein the antibody or antigen binding fragment binds the second extracellular loop of mammalian chemokine receptor 5 (CCR5).
109. (New) The test kit of Claim 99, wherein the antibody or antigen binding fragment can compete with a monoclonal antibody produced by the hybridoma deposited under ATCC Accession No. HB-12366 for binding to a chemokine receptor 5 (CCR5).
110. (New) The test kit of Claim 99, wherein the antigen binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.

REMARKS

Amendments to Claims

Applicants have cancelled Claims 1-73 and added claims 75-110. Entry of the amendment is respectfully requested.